SkinBioTherapeutics will "continue to be flexible enough to adapt to opportunities"

ADVERTISEMENT

Click to copy

Press release content from News Direct Corporation. The AP news staff was not involved in its creation.

Click to copy

Related topics

SkinBioTherapeutics will “continue to be flexible enough to adapt to opportunities”

PRESS RELEASE: Paid content from News Direct Corporation

Press release content from News Direct Corporation. The AP news staff was not involved in its creation.

December 19, 2022 GMT

None

None

--News Direct--

SkinBioTherapeutics PLC (AIM:SBTX) chief executive Stuart Ashman speaks to Proactive after announcing the raising of £2.5mln via a placing of new shares. He reveals what the company intends to do with the new funding, that may be augmented by a further £1mln from a retail offer. Ashman says that SkinBioTherapeutics “has always been and always will continue to be flexible enough to adapt to opportunities as and when they come [its] way.”

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/skinbiotherapeutics-will-continue-to-be-flexible-enough-to-adapt-to-opportunities-275923408